scispace - formally typeset
A

Ana Félix

Researcher at Instituto Português de Oncologia Francisco Gentil

Publications -  97
Citations -  5021

Ana Félix is an academic researcher from Instituto Português de Oncologia Francisco Gentil. The author has contributed to research in topics: Cervical cancer & Cancer. The author has an hindex of 24, co-authored 91 publications receiving 4176 citations. Previous affiliations of Ana Félix include University of Texas MD Anderson Cancer Center & Nova Southeastern University.

Papers
More filters
Journal ArticleDOI

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

Silvia de Sanjosé, +62 more
- 01 Nov 2010 - 
TL;DR: HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines, according to this largest assessment of HPV genotypes to date.
Journal ArticleDOI

HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients

Xavier Castellsagué, +61 more
TL;DR: This large international study to estimate fractions of head and neck cancers attributable to human papillomavirus (HPV-AFs) using six HPV-related biomarkers of viral detection, transcription, and cellular transformation confirms the important role ofHPVs in oropharyngeal cancer and drastically downplays the previously reported involvement of HPVs in the other HNCs.
Journal ArticleDOI

Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva

Silvia de Sanjosé, +52 more
TL;DR: Combined data from HPV-DNA and p16(INK4a) testing are likely to represent a closer estimate of the real fraction of IVC induced by HPV, indicating that HPV contribution in invasive vulvar cancer has probably been overestimated.
Journal ArticleDOI

Role of Human Papillomavirus in Penile Carcinomas Worldwide

TL;DR: About a third to a fourth of penile cancers were related to HPV when considering HPV DNA detection alone or adding an HPV activity marker, respectively, and the observed HPV type distribution reinforces the potential benefit of current and new HPV vaccines in the reduction of HPV-related penile neoplastic lesions.